| Project/Area Number |
17K16820
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Aichi Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | artemisinin / 腎細胞癌 / renal cell carcinoma |
|---|
| Outline of Final Research Achievements |
Administration of dihydroartemisinin and artesunate showed tumor growth suppression in all RCC cell lines. But artemisinin and deoxyartemisinin did not show growth suppression. Cell cycle analysis showed that cell cycle distribution after treatment by dihydroartemisinin or artesunate indicated a rise of percentage of cells in G2-M phase. SK-RC-7 cells treated with artesunate accumulated at the G2-M (45.4%) phase, compared with mock-treated cells (20.8%). Artesunate induced apoptosis on SK-RC-7 cells by the meaning of Annexin V analysis.Dihydroartemisinin and artesunate inhibited tumor proliferation of RCC cell lines. This study suggested that artemisinin derivatives could be an effective remedy to advanced RCC.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究によって、artemisinin誘導体は、腎細胞癌細胞の増殖を抑制することが示された。これによって、腎細胞癌治療のひとつとして、artemisinin誘導体の使用の可能性が示唆された。artemisinin誘導体は、現在マラリア治療薬として使用されており、腎癌治療においても離床的に使用しやすい可能性が考えられ、腎癌治療の発展に寄与する期待がある。
|
